Physician profile
Stephen M Long
NPI 1710211891
$9,385.08
in general payments reported to CMS, 2019-2025
42 companies · $1,886 in 2025
The $1,886 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,470 · 2022: $1,798 · 2023: $2,056 · 2024: $2,174 · 2025: $1,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,116.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,436.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $985.84 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $683.03 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $611.49 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $605.82 | 2021-2025 | |
| Pfizer INC. | $568.51 | 2021-2025 | |
| Amgen INC. | $557.41 | 2021-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $510.18 | 2021-2025 | Jardiance |
| Abbott Laboratories | $459.36 | 2021-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $330.21 | 2021-2025 | Trintellix |
| Astellas Pharma US INC | $268.33 | 2021-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $255.01 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $177.45 | 2021-2025 | Spravato |
| Merck Sharp & Dohme LLC | $177.10 | 2021-2023 | Belsomra, Steglatro, Lagevrio |
| Biohaven Pharmaceutical Holding Company LTD. | $151.40 | 2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $141.67 | 2023-2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $136.94 | 2022-2025 | Keveyis, Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $115.49 | 2021-2025 | Eliquis |
| Esperion Therapeutics, INC. | $114.24 | 2021-2024 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107.84 | 2024-2025 | Caplyta |
| Corium, LLC | $99.34 | 2023-2025 | Azstarys |
| Shield Therapeutics INC | $92.20 | 2023-2025 | Accrufer |
| Kowa Pharmaceuticals America, INC. | $87.35 | 2021-2023 | Livalo, Seglentis |
| Dexcom, INC. | $85.09 | 2021-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $71.02 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $67.68 | 2021 | |
| Jazz Pharmaceuticals INC. | $63.12 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.81 | 2022-2025 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $44.79 | 2025 | Auvelity |
| Lundbeck LLC | $40.67 | 2023-2025 | Vyepti, Rexulti |
| Vanda Pharmaceuticals INC. | $38.11 | 2024 | Fanapt |
| Sumitomo Pharma America, INC. | $37.62 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $29.31 | 2022 | |
| Almatica Pharma LLC | $26.73 | 2021-2022 | |
| Eisai INC. | $24.94 | 2021 | |
| Nevro Corp. | $24.67 | 2022 | |
| Sanofi-Aventis U.S. LLC | $23.61 | 2021 | |
| Inspire Medical Systems, INC. | $21.89 | 2025 | Inspire |
| Horizon Therapeutics Plc | $15.82 | 2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $13.34 | 2023 | Strensiq |
| Phathom Pharmaceuticals, INC. | $13.12 | 2024 | Voquezna |
| Clarus Therapeutics INC. | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.